Latest Research And Development News

Page 18 of 115
Adherium's FY2026 results show strong revenue gains from US remote patient monitoring but increased losses due to higher operating costs and commercial expansion.
Ada Torres
Ada Torres
31 Aug 2026
Nimy Resources reports metallurgical tests achieving 84% gallium and up to 95% rare earth extraction at its Mons Project Block 3, underpinning proprietary processing technology and feeding into a scoping study.
Maxwell Dee
Maxwell Dee
31 Aug 2026
Streamplay Studio Limited surged past $13 million in revenue for FY26, driven by a full year of Noodlecake Studios' contribution, while trimming its net loss by 15%.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Audeara Limited delivered record FY26 revenue of $4.45 million, driven by a 45% surge in Australian wholesale sales and progress in AI audio licensing with OPTEK Microelectronics. The company narrowed its loss and advanced Auracast deployments across retirement villages and education sectors.
Victor Sage
Victor Sage
31 Aug 2026
Ion Video Limited narrowed its loss to $4.52 million in FY2026, slashing operating costs and shifting focus to intellectual property licensing while strengthening its balance sheet and securing funding through to late 2027.
Sophie Babbage
Sophie Babbage
31 Aug 2026
IODM Limited’s FY26 results show solid revenue gains led by UK education, but losses persist with a net deficiency in equity raising going concern questions.
Sophie Babbage
Sophie Babbage
31 Aug 2026
Ceretas Limited posted a $1.63 million net loss for FY26 on $1.28 million revenue from government grants, advancing its clinical-stage Alzheimer’s ultrasound platform. The company completed an $8 million IPO in July to fund pivotal trials and device development.
Ada Torres
Ada Torres
31 Aug 2026
Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.
Victor Sage
Victor Sage
31 Aug 2026
PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.
Ada Torres
Ada Torres
28 Aug 2026
Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.
Ada Torres
Ada Torres
28 Aug 2026
First Graphene lifted revenue by 15% to $537,594 for FY26 while narrowing its net loss slightly to $5.4 million. Key acquisitions and a landmark China cement distribution MOU set the stage for commercial expansion.
Maxwell Dee
Maxwell Dee
28 Aug 2026
OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.
Ada Torres
Ada Torres
28 Aug 2026

Browse the archive

Full archive